Stockscreener 앱 받기
5.46
1.68%
0.09
시간 외 거래:
5.46
전일 마감가:
$5.37
열려 있는:
$5.42
하루 거래량:
33,731
Relative Volume:
0.69
시가총액:
$98.24M
수익:
-
순이익/손실:
$-9.46M
주가수익비율:
-0.1886
EPS:
-28.9457
순현금흐름:
$-8.70M
1주 성능:
+7.80%
1개월 성능:
+35.96%
6개월 성능:
+77.27%
1년 성능:
+36.17%
1일 변동 폭
$5.38
$5.58
1주일 범위
$4.76
$5.745
52주 변동 폭
$2.66
$7.00
알테리티 테라퓨틱스 Stock (ATHE) Company Profile
Compare ATHE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATHE
Alterity Therapeutics Ltd Adr
|
5.42 | 97.33M | 0 | -9.46M | -8.70M | -28.95 |
VRTX
Vertex Pharmaceuticals Inc
|
498.01 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
624.72 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
908.33 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.67 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
187.51 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
알테리티 테라퓨틱스 Stock (ATHE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-03 | 다운그레이드 | The Benchmark Company | Speculative Buy → Hold |
| 2024-12-12 | 개시 | Maxim Group | Buy |
알테리티 테라퓨틱스 주식(ATHE)의 최신 뉴스
[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) | ATHE SEC FilingForm 6-K - Stock Titan
Jones Trading initiates Alterity Therapeutics stock with buy rating - Investing.com
Alteriry Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:ATHE) - TradingView
Is Allarity Therapeutics, Inc. (ALLR) outperforming other medical stocks this year? - MSN
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder - Sahm
Insights: Alterity Therapeutics Ltd (ASX:ATHDA) - smallcaps.com.au
ATHEAlterity Therapeutics Ltd ADR Volatility & Greeks - Finviz
Alterity Therapeutics (NASDAQ: ATHE) sets vote on 50:1 consolidation and large option, incentive issuances - Stock Titan
Alterity Therapeutics appoints Ann Cunningham to board - Investing.com
Alterity Therapeutics appoints Ann Cunningham to board By Investing.com - Investing.com India
Nerves settle as oil drops - The Cairns Post
Alterity Therapeutics Receives Positive FDA Feedback for ATH434 Phase 3 MSA Program - smallcaps.com.au
ATA Inc. (NASDAQ:AACG) Sees Large Decline in Short Interest - Defense World
Actelis Networks, Inc. (NASDAQ:ASNS) Sees Large Decline in Short Interest - Defense World
Purple Biotech Stock Scheduled to Reverse Split on Monday, March 2nd (NASDAQ:PPBT) - Defense World
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 188.7% in February - Defense World
Ameritas Investment Partners Inc. Raises Stock Holdings in Kratos Defense & Security Solutions, Inc. $KTOS - Defense World
Analysts Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Price Target at $32.60 - Defense World
Alterity Therapeutics (NASDAQ:ATHE) Upgraded at Zacks Research - Defense World
Compass Minerals International, Inc. (NYSE:CMP) Receives $22.00 Consensus Price Target from Analysts - Defense World
Benjamin Edwards Inc. Acquires 2,629 Shares of iShares Russell 1000 Value ETF $IWD - Defense World
AOT Growth & Innovation ETF (NASDAQ:AOTG) Short Interest Update - Defense World
Allspring Global Investments Holdings LLC Purchases 1,956,470 Shares of Allspring Special Large Value ETF $ASLV - Defense World
CaixaBank (OTCMKTS:CAIXY) Hits New 52-Week High – Still a Buy? - Defense World
Alterity Therapeutics (NASDAQ:ATHE) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Insights: Alterity Therapeutics Ltd (ASX:ATH) - smallcaps.com.au
Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434 - Finviz
Quantum Biopharma (QNTM) Short Interest & Short Float | Updated May 2026 - MarketBeat
Liminatus Pharma (LIMN) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
ATHE SEC FilingsAlterity Therapeutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Alterity Therapeutics reports Phase 2 data at MSA Congress By Investing.com - Investing.com South Africa
Alterity Therapeutics announces trading halt - Investing.com
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
symbol__ Stock Quote Price and Forecast - CNN
- SEC.gov
Cadrenal Therapeutics (CVKD) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Bullfrog AI (BFRG) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology By Investing.com - Investing.com India
Imunon (IMNN) Short Interest & Short Float | Updated May 2026 - MarketBeat
Quince Therapeutics (QNCX) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy - Barchart.com
What is the current Price Target and Forecast for Alterity Therapeutics LimitedSponsored ADR (ATHE) - Zacks Investment Research
Mainz Biomed (MYNZ) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
These stocks are moving in today's pre-market session - ChartMill
Portage Biotech (PRTG) Short Interest & Short Float | Updated Apr 2026 $PRTG - MarketBeat
Which stocks are gapping on Wednesday? - ChartMill
Top movers in Thursday's after hours session - ChartMill
Friday's session: gap up and gap down stocks - ChartMill
Which stocks are moving before the opening bell on Tuesday? - ChartMill
Which stocks are moving after the closing bell on Friday? - ChartMill
알테리티 테라퓨틱스 (ATHE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.99%
0.57%
자본화:
|
볼륨(24시간):